Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
about
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisNon-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisRifaximin for people with hepatic encephalopathyNonabsorbable disaccharides for hepatic encephalopathyTreatment of hepatic encephalopathy: it's not lactuloseInflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosisManagement options in decompensated cirrhosisManagement of overt hepatic encephalopathyThe conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosisManagement of Hepatic Encephalopathy: A PrimerRifaximin for the treatment of hepatic encephalopathyHepatic Encephalopathy: From the Pathogenesis to the New Treatments.Ammonia toxicity to the brain.Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.Management of Neurologic Manifestations in Patients with Liver Disease.Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veinsCirrhosis and its complications: evidence based treatment.Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy.Integration of palliative care in end-stage liver disease and liver transplantationErythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind studyHepatic encephalopathy: from pathophysiology to treatment.Rifaximin pharmacology and clinical implications.Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.The diagnosis and treatment of minimal hepatic encephalopathyRevision and update on clinical practice guideline for liver cirrhosis.Update on the management of cirrhosis - focus on cost-effective preventative strategiesPathophysiology and management of hepatic encephalopathy.How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist.Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes.Rifaximin for treatment of hepatic encephalopathy.Rifaximin in the treatment of hepatic encephalopathy.Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patientsManagement and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Emerging drugs for hepatic encephalopathy.Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial.Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot studyUtility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.Pharmacotherapy of hepatic encephalopathy in cirrhosis.
P2860
Q24185782-1656CECD-24DF-42A7-8FCA-ED5A0BE96746Q24185895-5ED604F4-89F8-4C8E-BB25-D08399BE7FF3Q24187627-E5837329-E65B-4DB0-8F23-B89A91B48963Q24247141-5C5157A4-A7AF-4BC2-9B66-BEE49147FDA2Q24563355-3536376E-9848-4A08-A97C-080AA9279A67Q26778000-1F7988A0-16C4-467A-8F7D-CB297A7CE578Q26800238-B5CA1300-C610-4C18-9E9B-1B8C0CEC1F8FQ26830789-376FD894-D837-431A-AEC3-79EFAABA129EQ27009164-1E5439C6-C0F8-4F63-9876-4322BA572345Q28275197-0E2307C1-7CBE-4FE0-9B8A-943DE415A01EQ28288610-81AA73A3-AA07-473B-BB82-17F927364144Q30381016-EE5F51F2-50E6-44FB-9B89-05663DF73EFEQ30575263-C1F82517-FF0B-462B-A2BC-E6791C25762EQ30907818-EE69D6EC-0961-4BEA-9E58-85501D8D6ADEQ31108752-EB5CD9D5-1937-415D-9333-C3E237433B71Q31135843-234E9339-3FCA-48BA-8ABD-679C4B0B3398Q33383749-33EDD841-3D45-403F-94BB-D4DC2199E783Q33594931-EEAF3191-E07A-4409-850D-B5941FDEFF66Q33628162-7915804F-B09B-4C34-97ED-870A81601480Q34252801-6E49CA28-61BA-40AA-8294-5D32B3481C18Q34499979-BA0F9A39-EC73-45AE-817C-8A856D405A34Q34550014-4C7D038C-259A-4D3E-B8B8-3E299A3461D7Q34565090-E50A20DE-7DC4-4AC7-8F6D-AD3C4A214895Q34607677-8FE16FCF-C466-4BC6-A7CF-B0895936B6ABQ34996031-F55FB989-700A-4FE0-94E4-7E727F13696EQ35865294-1C9DEA47-3CED-4741-8C70-8712AB23F375Q35890613-7DDB490D-6226-44A1-BA6C-8FFDF872CCABQ36784836-9D47B69E-6CCF-49F3-9DA7-AE3AEF819238Q36823626-2C86B843-48CE-4CE6-8468-3AE0037564C3Q36947936-2387DA88-8B7E-4231-92A3-6686821EE103Q37353473-C9FFB09F-2A20-49FF-B589-4D007DFE0289Q37353572-BD7EDDE1-089C-45BC-BB01-754D336243E5Q37355818-13EFED59-6272-4903-B38B-45AAB57B9FE9Q37361451-742E50F7-E618-44E0-B9D7-9E5189149A9BQ37489472-DA07434D-0F45-409F-835E-DF19756BFC70Q37529838-1CD6EE83-FFE0-46E6-87FA-44B3AEB799A3Q37641048-251656C1-823E-458B-AF2B-C87AABF95E0CQ37660968-65E4E11F-2F67-4BE2-BCA2-169FC1CC1556Q37678916-B1ED0DFF-9DC4-4949-9D34-EB4A480E9269Q37729173-351995CA-2B19-43C5-8D0B-3AB0F366F5F0
P2860
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Non-absorbable disaccharides f ...... c review of randomised trials.
@ast
Non-absorbable disaccharides f ...... c review of randomised trials.
@en
type
label
Non-absorbable disaccharides f ...... c review of randomised trials.
@ast
Non-absorbable disaccharides f ...... c review of randomised trials.
@en
prefLabel
Non-absorbable disaccharides f ...... c review of randomised trials.
@ast
Non-absorbable disaccharides f ...... c review of randomised trials.
@en
P2860
P1433
P1476
Non-absorbable disaccharides f ...... c review of randomised trials.
@en
P2093
Bodil Als-Nielsen
P2860
P356
10.1136/BMJ.38048.506134.EE
P407
P577
2004-03-30T00:00:00Z